Syringaresinol Protects against Type 1 Diabetic Cardiomyopathy by Alleviating Inflammation Responses, Cardiac Fibrosis, and Oxidative Stress.
Guangru LiLei YangLifeng FengJiu YangYafei LiJiale AnDihua LiYang XuYang GaoJing LiJie LiuLiang YangZhi QiPublished in: Molecular nutrition & food research (2020)
The results indicated that SYR could be a potential therapeutic agent for the treatment of diabetic cardiomyopathy by inhibiting inflammation, fibrosis, and oxidative stress. The signaling pathway of Keap1/Nrf2 and TGF-β/Smad could be used as therapeutic targets for diabetic complications.
Keyphrases
- oxidative stress
- signaling pathway
- induced apoptosis
- type diabetes
- diabetic rats
- wound healing
- dna damage
- ischemia reperfusion injury
- epithelial mesenchymal transition
- heart failure
- transforming growth factor
- left ventricular
- risk factors
- pi k akt
- small molecule
- heat shock
- cell proliferation
- atrial fibrillation
- replacement therapy
- smoking cessation